Sign in
CompletedPhase 4

Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa

Key facts

Who runs it
GlaxoSmithKline
Where
Burkina Faso, Ghana, Kenya, Malawi, Senegal, and Tanzania10 sites in 6 countriesChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
54,115 people enrolled
Started
22 Oct 2014
Ended
6 Jul 2024
Type of study
Interventional, 10 groups
Treatments tested
  • Assessment of body temperature
  • Blood sampling
Record updated
24 July 2025

Who can take part

Age
6 months to 9 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • Participants whose parent(s)/Legally Acceptable Representative(s) [LAR(s)], in the opinion of the investigator, could and would comply with the requirements of the protocol
  • A male or female aged 6 months to under 10 years at the time of the survey
  • Signed informed consent or thumb-printed and witnessed informed consent was obtained from the parent(s)/LAR(s) of the child

Who cannot take part

  • Had current active participation in any trial involving administration of an investigational malaria vaccine or malaria drug
  • Child was in care

This trial has no sites in United States.

It has sites in 6 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

This epidemiology study was conducted in parallel with the EPI-MAL-002 (NCT02374450) and EPI-MAL-003 (NCT03855995) studies, enrolling participants from the same health and demographic surveillance system (HDSS) (or equivalent system) populations. The co-primary objectives were to produce longitudinal estimates of parasite prevalence in humans and to record the usage of malaria control measures in areas where the EPI-MAL-002 and EPI-MAL-003 studies were conducted.

The 10 groups in the trial

  • Survey 1 GroupOther group

    Participants aged 6 months to \<10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 1.

    Treatment: Assessment of body temperature and Blood sampling

  • Survey 2 GroupOther group

    Participants aged 6 months to \<10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 2.

    Treatment: Assessment of body temperature and Blood sampling

  • Survey 3 GroupOther group

    Participants aged 6 months to \<10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 3.

    Treatment: Assessment of body temperature and Blood sampling

  • Survey 4 GroupOther group

    Participants aged 6 months to \<10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 4.

    Treatment: Assessment of body temperature and Blood sampling

  • Survey 5 GroupOther group

    Participants aged 6 months to \<10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 5.

    Treatment: Assessment of body temperature and Blood sampling

  • Survey 6 GroupOther group

    Participants aged 6 months to \<10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 6.

    Treatment: Assessment of body temperature and Blood sampling

  • Survey 7 GroupOther group

    Participants aged 6 months to \<10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 7.

    Treatment: Assessment of body temperature and Blood sampling

  • Survey 8 GroupOther group

    Participants aged 6 months to \<10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 8.

    Treatment: Assessment of body temperature and Blood sampling

  • Survey 9 GroupOther group

    Participants aged 6 months to \<10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 9.

    Treatment: Assessment of body temperature and Blood sampling

  • Survey 10 GroupOther group

    Participants aged 6 months to \<10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 10.

    Treatment: Assessment of body temperature and Blood sampling

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Epidemiology Study to Assess Plasmodium Falciparum Parasite Prevalence and Malaria Control Measures in Catchment Areas of Two Interventional Studies Pre- and Post RTS,S/AS01E Introduction (EPI MAL-002 and EPI-MAL-003) to Assess, in Field Conditions, Vaccine Benefit: Risk in Children in Sub Saharan Africa
Record updated
24 July 2025